Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPHASE trial of nizaracianine triflutate for intraoperative ureter visualization
NL-OMON60621Phase 3Recruiting
- Sponsor
- Curadel Surgical Innovations, Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nizaracianine triflutate in None (2 arms), sponsored by Curadel Surgical Innovations, Inc. Primary endpoints: Near-optimal dose determination, Safety assessment and 1 more. Started May 2024; status: recruiting.
02
Drugs
nizaracianine triflutate
Beyond the preview
Go deeper on NL-OMON60621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60621.